An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
Terminated · Phase 2 · NCT03712787
Conditions: Alzheimer's Disease
At a glance
- Research payments reported, 2025
- $2,128
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 364
About the trial
- Sponsor
- AbbVie
- Tested
- Tilavonemab (drug)
- Dates
- Started 2019-03-22; completion 2021-09-30
- Results posted
- Yes
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.
From ClinicalTrials.gov, last updated 2022-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2,128 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.